Cancer Center, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
J Zhejiang Univ Sci B. 2012 Sep;13(9):663-75. doi: 10.1631/jzus.B1100340.
Colorectal cancer remains one of the most common types of cancer and leading causes of cancer death worldwide. Although we have made steady progress in chemotherapy and targeted therapy, evidence suggests that the majority of patients undergoing drug therapy experience severe, debilitating, and even lethal adverse drug events which considerably outweigh the benefits. The identification of suitable biomarkers will allow clinicians to deliver the most appropriate drugs to specific patients and spare them ineffective and expensive treatments. Prognostic and predictive biomarkers have been the subjects of many published papers, but few have been widely incorporated into clinical practice. Here, we want to review recent biomarker data related to colorectal cancer, which may have been ready for clinical use.
结直肠癌仍然是世界上最常见的癌症类型之一，也是癌症死亡的主要原因。尽管我们在化疗和靶向治疗方面取得了稳步进展，但有证据表明，大多数接受药物治疗的患者都经历了严重、衰弱甚至致命的药物不良事件，这些事件的影响远远超过了治疗的益处。合适的生物标志物的识别将使临床医生能够为特定患者提供最合适的药物，并使他们免受无效和昂贵的治疗。预后和预测生物标志物一直是许多已发表论文的主题，但很少有被广泛纳入临床实践。在这里，我们想回顾一下与结直肠癌相关的最近的生物标志物数据，这些数据可能已经准备好用于临床应用。
